Prognostic factors for metastatic testicular germ cell tumours: the Memorial Sloan-Kettering cancer model.
Since November 1982, patients treated at Memorial Hospital for advanced germ cell tumours have been allocated to good or poor risk clinical trials by the use of a mathematical model. A probability of complete response (CR) is based upon a patient's actual pre-treatment values of LDH and HCG and the number of metastatic sites. In good risk trials, a regimen consisting of four cycles of etoposide+cisplatin results in a durable proportion of CR of about 90% and causes minimal toxicity. Modifications of standard dose regiments have failed to increase the CR proportion in poor risk patients despite greater toxicity. The data show that about 10% of good risk patients will die despite favourable prognostic features, and about 35% of poor risk patients will achieve a durable CR with standard therapy despite unfavourable clinical characteristics. Therefore better markers of prognosis are needed. Two addition categories of markers are under study at Memorial Hospital. Firstly, the half-life decline of AFP and HCG (a 'post-treatment' marker) measured during the first two months of initial therapy is strongly associated with the likelihood of a CR. A prolonged decline of either AFP or HCG resulted in an inferior survival in both good and poor risk patients. Because few good risk patients had a prolonged marker half-life decline, this observation is being confirmed prospectively in an ongoing randomized trial. However, in poor risk patients, a prolonged half-life marker decline now results in an immediate change to high-dose therapy with autologous stem cell rescue.(ABSTRACT TRUNCATED AT 250 WORDS)
- 원문이 없습니다.
- Karger AG : 저널
유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.
원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.
NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.
- 이 논문과 함께 출판된 논문 + 더보기